DELRAY BEACH, Fla., April 19, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), an emerging growth company and developer of advanced technologies for diabetes management as well as sophisticated airborne bio-threat detection systems for America's homeland defense, today announced its FDA-cleared iglucose® mobile health system for diabetes management will be featured at the CTIA Emerging Technology (E-Tech) Awards Showcase at the International CTIA Wireless 2012 show from May 8-10, 2012
at the Ernest N. Morial Convention Center in New Orleans, LA. iglucose will be showcased within the category entitled Enterprise & Vertical Market Solution: Healthcare & Wellness.
PositiveID's FDA-cleared iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating data from glucometers to the iglucose diabetes management portal, glucose readings can be shared with family members and healthcare professionals. This makes it possible to improve care in a cost-effective manner. iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the
self-management of their condition. Family members have greater peace of mind; now parents of children with diabetes can receive text messages to let them know their children are testing while at school. iglucose does not require the use of a cell phone or a wireless plan.
iglucose was designed with the needs of healthcare professionals and people with diabetes in mind. It is simple to use and conveniently fits within a pocket or purse. Usability tests conducted as part of the iglucose FDA review process demonstrated 100 percent of consumers were able to use the device regardless of their age. After initial enrollment there are no technology requirements for the end user. Users simply connect their glucometer to iglucose and push a button. The iglucose system creates a variety of reports and communicates according to the user's preferences via online access, email, fax or SMS text.
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters such as Johnson & Johnson LifeScan®, Abbott FreeStyle®, Bayer Contour ®, and Nipro Diagnostic™ True™ monitoring systems to a secure database via wireless cellular technology. The Company is continually adding to this list of supported glucose meters. For more information on iglucose, visit www.iglucose.com.
The International CTIA Wireless show draws more than 40,000 qualified attendees every year, occupies more than 300,000 sq. ft. of exhibit space, hosts over 1,000 exhibitors, attracts more than 1,100 press and analysts worldwide, and offers top-level speakers and the most comprehensive educational programming in the industry. CTIA—The Wireless Association® (www.ctia.org) is an international organization representing the wireless communications industry.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition; the likelihood that iglucose makes it possible to improve care in a cost-effective manner; the likelihood that iglucose eliminates the burden of keeping logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition; the likelihood that family members have greater peace of mind; the likelihood that the Company is continually adding to this list of supported glucose meters; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and
as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize its diabetes management products including iglucose, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on May 13, 2011, August 15, 2011
, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: PositiveID Corporation
Trilogy Capital Partners, Inc.
Darren Minton, President
Source: PositiveID Corporation
News Provided by Acquire Media